Larimar Therapeutics, Inc. (NASDAQ:LRMR), a clinical-stage pharmaceutical company with a market capitalization of $221 million, has issued performance-based restricted stock units (PSUs) to its top ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases ...

As previously reported, Truist initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target Despite “promising” ...

Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in ...

Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia: Bala Cynwyd, Pennsylvania Saturday, January 25, 2025, 15: ...

Larimar Therapeutics reports promising FXN level increases with 25 mg nomlabofusp, advancing towards dose escalation for Friedreich's Ataxia treatment.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Fintel reports that on January 29, 2025, Truist Securities initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a Buy recommendation. As of January 29, 2025, the average one-year price ...

On Monday, shares of Larimar Therapeutics experienced a significant decline following a data update from its ongoing Friedreich’s ataxia treatment study. The update included reports of serious ...

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and ...

Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases ...